Krueger W A, Ruckdeschel G, Unertl K
Department of Anaesthesiology, Tübingen University Hospital, Germany.
Antimicrob Agents Chemother. 1997 Aug;41(8):1725-30. doi: 10.1128/AAC.41.8.1725.
Ciprofloxacin, when given intravenously (i.v.), is secreted in significant amounts via the mucosa into the intestinal lumen. Sucralfate inhibits the antimicrobial activity of ciprofloxacin. The effect of combined therapy on the intestinal flora was investigated in 16 healthy volunteers. They were randomly assigned to two groups. Group A received 2 g of sucralfate orally three times a day for 7 days and 400 mg of ciprofloxacin i.v. twice a day (b.i.d.) starting 3 days after the sucralfate administration began. Group B was given only 400 mg of ciprofloxacin i.v. b.i.d. for 4 days. A total of 9 stool samples were collected from each subject beginning the week before ciprofloxacin was administered and on days -1, 1, 2, 3, 4, 7, 9, and 10 or 11 after commencement of the infusion period. The aerobic fecal flora was determined by standard microbiological methods. Measurements of fecal ciprofloxacin levels were based on high-performance liquid chromatography. Counts of bacteria of the family Enterobacteriaceae decreased in all subjects and were below 10(2) CFU/g in eight of eight subjects (group A) and six of eight subjects (group B) on day 4, but they returned to normal in all but one subject (group A) 10 days after the last infusion. The decreases in levels of bacteria of the family Enterobacteriaceae were not significantly different in groups A and B (Kaplan-Meier test). Staphylococci and nonfermenters responded variably, enterococci and lactobacilli remained unchanged, and candida levels increased transiently in four subjects (two in each group). Maximum fecal drug levels ranged from 251 to 811 microg/g. No significant difference could be found between the two groups. The i.v. application of ciprofloxacin eliminates intestinal bacteria of the family Enterobacteriaceae in a rapid and selective manner. This effect is not affected by simultaneous oral application of sucralfate.
环丙沙星静脉注射时,会通过黏膜大量分泌至肠腔。硫糖铝会抑制环丙沙星的抗菌活性。在16名健康志愿者中研究了联合治疗对肠道菌群的影响。他们被随机分为两组。A组每天口服3次2g硫糖铝,共7天,在开始服用硫糖铝3天后,每天静脉注射2次400mg环丙沙星。B组仅每天静脉注射2次400mg环丙沙星,共4天。从每位受试者在环丙沙星给药前一周开始,以及在输注期开始后的第-1、1、2、3、4、7、9和10或11天,共采集9份粪便样本。通过标准微生物学方法测定需氧粪便菌群。粪便中环丙沙星水平的测定基于高效液相色谱法。所有受试者的肠杆菌科细菌计数均下降,在第4天,A组8名受试者中的8名和B组8名受试者中的6名低于10(2)CFU/g,但在最后一次输注10天后,除一名受试者(A组)外,所有受试者的肠杆菌科细菌计数均恢复正常。A组和B组肠杆菌科细菌水平的下降无显著差异(Kaplan-Meier检验)。葡萄球菌和非发酵菌的反应各不相同,肠球菌和乳酸杆菌保持不变,4名受试者(每组2名)的念珠菌水平短暂升高。粪便药物最高水平在251至811μg/g之间。两组之间未发现显著差异。静脉注射环丙沙星能快速、选择性地清除肠道中的肠杆菌科细菌。这种作用不受同时口服硫糖铝的影响。